Sorry - There were no pages found that contain that search phrase.
|
|
|
||||||
|
|
Showing Treatment 1 to 11 of 11 | |
Location | |
Last Updated | |
|
| ||||||||
|
Details | |
Phase I/II Study of Sorafenib and Temsirolimus (CCI-779) in Patients With Recurrent Glioblastoma | |
Bismarck, ND USA | |
10/09/2008 | |
|
|
|
||||||
|
Details | |
Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma | |
Minot, ND USA | |
04/11/2008 | |
| ||||||||
|
Details | |
Comprehensive Genetic Analysis Of Brain Tumors In Children. (A Non-Therapeutic Study) | |
Fargo, ND USA | |
10/12/2006 | |
|
|
|
||||||
|
Details | |
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | |
Fargo, ND USA | |
06/26/2006 | |
| ||||||||
|
Details | |
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | |
Bismarck, ND USA | |
06/26/2006 | |
|
|
|
||||||
|
Details | |
Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma | |
Bismarck, ND USA | |
06/26/2006 | |
| ||||||||
|
Details | |
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | |
Fargo, ND USA | |
06/26/2006 | |
|
|
|
||||||
|
Details | |
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | |
Bismarck, ND USA | |
06/26/2006 | |
| ||||||||
|
Details | |
Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma | |
Bismarck, ND USA | |
11/27/2005 | |
|
|
|
||||||
|
Details | |
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma | |
Fargo, ND USA | |
11/27/2005 | |
| ||||||||
|
Details | |
A Phase II Study of HLA-Matched Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma as Adoptive Allogeneic Immunotherapy | |
Fargo, ND USA | |
11/06/2005 | |
|
|
|
||||||
| ||||||||